As of 2024-10-04, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -0.73. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 326.84 mil USD. SAGE's TTM EBITDA according to its financial statements is -448.32 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 16.5x | 13.9x |
| Forward P/E multiples | 19.0x - 23.5x | 21.3x |
| Fair Price | (138.04) - (119.38) | (127.61) |
| Upside | -2074.8% - -1807.9% | -1925.6% |
| Date | EV/EBITDA |
| 2024-10-04 | -0.72 |
| 2024-10-03 | -0.73 |
| 2024-10-02 | -0.73 |
| 2024-10-01 | -0.72 |
| 2024-09-30 | -0.76 |
| 2024-09-27 | -0.77 |
| 2024-09-26 | -0.75 |
| 2024-09-25 | -0.73 |
| 2024-09-24 | -0.77 |
| 2024-09-23 | -0.76 |
| 2024-09-20 | -0.80 |
| 2024-09-19 | -0.85 |
| 2024-09-18 | -0.81 |
| 2024-09-17 | -0.80 |
| 2024-09-16 | -0.81 |
| 2024-09-13 | -0.84 |
| 2024-09-12 | -0.78 |
| 2024-09-11 | -0.80 |
| 2024-09-10 | -0.78 |
| 2024-09-09 | -0.79 |
| 2024-09-06 | -0.80 |
| 2024-09-05 | -0.82 |
| 2024-09-04 | -0.87 |
| 2024-09-03 | -0.85 |
| 2024-08-30 | -0.93 |
| 2024-08-29 | -0.88 |
| 2024-08-28 | -0.85 |
| 2024-08-27 | -0.88 |
| 2024-08-26 | -0.90 |
| 2024-08-23 | -0.92 |
| 2024-08-22 | -0.89 |
| 2024-08-21 | -0.96 |
| 2024-08-20 | -0.91 |
| 2024-08-19 | -0.97 |
| 2024-08-16 | -0.89 |
| 2024-08-15 | -0.91 |
| 2024-08-14 | -0.87 |
| 2024-08-13 | -0.89 |
| 2024-08-12 | -0.85 |
| 2024-08-09 | -0.87 |
| 2024-08-08 | -0.90 |
| 2024-08-07 | -0.91 |
| 2024-08-06 | -0.94 |
| 2024-08-05 | -1.00 |
| 2024-08-02 | -1.08 |
| 2024-08-01 | -1.11 |
| 2024-07-31 | -1.27 |
| 2024-07-30 | -1.25 |
| 2024-07-29 | -1.25 |
| 2024-07-26 | -1.27 |